
Aug 26, 2025, 15:45
Haystack MRD by Quest Diagnostics Received FDA Breakthrough Device Designation
Svetlana Nikic, Founder at Precision Oncology Consulting, shared a post by Frank Holtrup, Chief Technology Officer at Haystack Oncology, on LinkedIn, adding:
“Congratulations Haystack team, a Quest Diagnostics company for receiving breakthrough device designation by FDA for their MRD assay (aimed for use for stage II CRC patients).”
“Proud of the entire Haystack MRD™ by Quest Diagnostics® team for achieving this important milestone on our way to create a healthier world, one life at a time.”
More posts featuring Svetlana Nikic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 26, 2025, 15:24
Aug 26, 2025, 15:12
Aug 26, 2025, 15:05
Aug 26, 2025, 14:12
Aug 26, 2025, 14:04
Aug 26, 2025, 13:55